Ensoma

Drug Discovery · Boston, MA · Founded 2019 · Privately Held (backing)

Operator of a biotech company intended to develop a genomic medicine in vivo approach to engineer any or all blood and immune cells to cure diseases. Ensoma is based in Boston, MA and was founded in 2019. Its last reported valuation was $280 million in May 2023. It has raised $258 million across 3 recorded rounds; the latest was a $53 million Series B1 in Sep 2025.

Last reported valuation
$280.0M
Oct 2026
Priced at
—
Total raised
$258.0M
Last round
Later Stage VC (Series B1)
Sep 2025

Who backs Ensoma?

21 investors
InvestorType
Viking Global InvestorsAsset manager
F-Prime CapitalVenture capital
Alexandria Venture InvestmentsOther
Gates FoundationOther
Qatar Investment AuthorityAsset manager
Catalio Capital ManagementVenture capital
Cormorant Asset ManagementVenture capital
Mirae Asset Global InvestmentsAsset manager
RTW InvestmentsHedge fund
5AM VenturesPE / buyout
+ 11 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Ensoma investors

21 investors are on record for Ensoma, including Viking Global Investors, F-Prime Capital, Alexandria Venture Investments and Gates Foundation. By type, the record holds 4 venture capital firms and 3 asset managers. The Series B1 in Sep 2025 drew 14 investors.

Free account
More of Ensoma with a free account
  • ·The complete investor list: 21 names
  • ·Watch Ensoma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 21 firms already write checks for companies like Ensoma in drug discovery. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View